APO-SALVENT STERULES SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

SALBUTAMOL (SALBUTAMOL SULFATE)

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

R03AC02

INN (আন্তর্জাতিক নাম):

SALBUTAMOL

ডোজ:

1MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

প্রশাসন রুট:

INHALATION

প্যাকেজ ইউনিট:

2.5ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0108887007; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

1997-06-23

পণ্য বৈশিষ্ট্য

_Page 1 of 32_
PRODUCT MONOGRAPH
PR
APO-SALVENT RESPIRATOR SOLUTIONS
(SALBUTAMOL SULFATE SOLUTIONS BP)
PR
APO-SALVENT RESPIRATOR SOLUTION 50 MG IN 10 ML (5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 1.25 MG IN 2.5 ML (0.5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 2.5 MG IN 2.5 ML (1 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 5.0 MG IN 2.5 ML (2 MG/ML SALBUTAMOL)
BRONCHODILATOR,
Β
2
-ADRENERGIC STIMULANT
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
March 16, 2020
CONTROL # 236795
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................................................
10
OVERDOSAGE
..........................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................